Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

seases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clinical development plans and milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commissi
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
(Date:12/19/2014)... CAMBRIDGE, MA (PRWEB) December 18, 2014 ... adults in the United States suffer from one or ... arthritis, asthma, or cancer. Medication can address some of ... to daily activities that many sufferers face. While implanted ... surgery and stimulate the whole nerve, which can induce ...
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... CAMBRIDGE, Mass., Nov. 4 Genstruct Inc., ... mechanisms, networks and,biomarkers to better develop novel ... has become a member of The Biomarker ... Foundation for the,National Institutes on Health (FNIH), ...
... in specialty biologics development, TORONTO and CHARLOTTETOWN, ... Inc. have agreed to partner in the development ... treatments, with a goal of,advancing the project to ... to add to its portfolio of biologic products., ...
... Help Children Reach Normal Height, PRINCETON, N.J., Nov. ... them from growing to a normal height now have ... [rDNA origin] injection) for the treatment of short stature ... catch-up growth by,age 2-4 years., The U.S. Food ...
Cached Biology Technology:Genstruct Added to The Biomarker Consortium's Rapidly Growing Roster of Industry Experts 2Genstruct Added to The Biomarker Consortium's Rapidly Growing Roster of Industry Experts 3Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 3FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 4FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 5
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... to reach a compromise that outlaws reproductive cloning or ... potential abuse, prejudice and discrimination, according to authors of ... Institute of Advanced Studies ( www.ias.unu.edu ). A ... clone, coupled with freedom for nations to permit strictly ...
... University of Western Ontario is set to host Canadas ... Exercise Physiology (CSEP) Annual Scientific Conference. The four-day, ... November 17 at the London Convention Centre, for the ... of the countrys leading thinkers in the fields of ...
... 2007 Researchers at Childrens Hospital of Pittsburgh of UPMC ... study the effectiveness of oral insulin in preventing or delaying ... for the disease. The researchers want to determine if ... onset of type 1 diabetes in relatives of people who ...
Cached Biology News:Human clones: New U.N. analysis lays out world's choices 2Human clones: New U.N. analysis lays out world's choices 3Human clones: New U.N. analysis lays out world's choices 4Canadian Society of Exercise Physiology Annual Scientific Conference 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2
LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...
in vitro Translation, Accessory Products...
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Sheep Serum US Origin...
Biology Products: